Altogen Labs in the Investigation of miRNA expression of Acute Myeloid Leukemia

Publication [Download PDF]: Dmitriy Ovcharenko, Friedrich Stolzel, David Poitz, Fernando Fierro, Markus Schaich, Andreas Neubauer, Kevin Kelnar, Timothy Davison, Carsten Muller-Tidow, Christian Thiede, Martin Bornhauser, Gerhard Ehninger, David Brown, and Thomas Illmer. Experimental Hematology 2011; 39:1030–1042

Acute myeloid leukemia (AML) is a cancer that affects hematopoietic stem cells and often results in the accumulation of immature or abnormal blood cells that interfere with healthy blood cell function. AML patients are categorized and treated differently based on cytogenetic alterations; AML blast chromosomal aberrations have been linked to relapse or treatment failure. While intermediate risk (IR) AML patience have a normal karyotype, this is often accompanied by additional mutations, for example in FLT3, CEBP/α, or NPM1, which can be used to predict prognosis and treatment response. Methods for discriminating subtypes of AML are critical to successful treatment, and Ovcharenko et al. (Experimental Hematology, 2011) analyzed differential expressions of microRNA (miRNA) in AML/IR patients. Chromosomal abnormalities are known to alter miRNA expression levels, which in turn regulate gene expression levels.  Specifically in hematopoietic cells, miRNAs have been seen to regulate differentiation and proliferation. The sensitive nature of miRNA expression profiles may prove to have a higher sensitivity than karyotyping or complementary DNA microarrays for characterizing AML subtypes.

With services provided by Altogen Labs, the 2011 Experimental Hematology study identified miR-10a, a miRNA that is upregulated in AML nucleophosmin 1 (NPM1) mutant samples, and analyzed in vitro functional consequences of this effect. Microarray analysis and quantitative reverse transcription polymerase chain reaction (qRT-PCR) of miRNAs were performed to compare normal to AML IR patient samples and led to the identification of miR-10a as upregulated in ML samples with mutant NPM1. qRT-PCR, western blotting, proliferation assays, overexpression studies, anti-miR-10a inhibition studies and mutant studies were used to analyze the potential effect of miR-10a cellular gene expression and signaling. Overall, data suggested that the characteristic overexpression of miR-10a in NPM1-mutant AML patients may result in cellular changes mediated via murine double minute 4 (MDM4) and the p53 signaling pathway. Altogen Laboratories is Texan contract research organization (CRO) offering services such as those outlined above and more. Altogen Labs is equipped to provide RNAi services (siRNA encapsulation, stable gene knockdown, transient transfection, shRNA construction, inducible knockdown, etc.), stable protein overexpression cell line, cryopreservation cell banking, IC50 toxicology studies, a wide array of xenograft studies and more. Professional scientists at Altogen Labs are trained to provide top quality research at competitive pricing. At Altogen Labs we understand time is important, which is why we offer instant quotes as well as any desired consulting throughout the research process, from experiment design to analysis, in order to provide clients with a seamless and efficient experience.

Alofanib Preclinical Research Study

Publication [Download PDF]: Tyulyandina, A., Harrison, D., Yin, W. et al. Invest New Drugs (2017) 35: 127. Ovarian cancer is notorious for its poor prognosis; five-year survival rates for are 40% and 18% for stages III and IV, respectively. Ovarian cancer classifications are defined by the origin cell types and include papillary serous histology,… Continue Reading

Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Orthotopic glioma xenograft model

Altogen Labs provides in vivo imaging services for drug development and biodistribution studies: U87 orthotopic glioma xenograft animal model study  by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78748 USA Download full text PDF:  Introduction In vivo imaging has emerged as a critical tool in visualization in preclinical research studies related to the development… Continue Reading

Xenograft Models for Preclinical Research: From Translational Studies to Clinical Trials

AUSTIN, TX, December 17, 2018 Altogen Labs, a biotechnology laboratory focused on the development of innovative cancer therapeutics, today announced the addition of new CDX models (MDA-MB-157, MDA-MB-453, U87, and OVCAR-3). The addition of these xenograft models further increases Altogen Labs’ product line in breast and ovarian cancer, as well as glioblastoma to 89 CDX,… Continue Reading

Medical Discovery and Innovation: Altogen Labs Preclinical CRO Services

Altogen Labs Preclinical CRO Services Altogen Labs (, an Austin, TX based contract research organization (CRO) offers preclinical laboratory services to pharmaceutical, biotechnology, and academic researchers worldwide to support and accelerate medical discovery and research studies. Our Good Laboratory Practice (GLP)-compliant laboratory located at 11200 Manchaca Rd, Suite 203, Austin TX offers services for drug toxicology, drug efficacy, drug… Continue Reading

Altogen Labs Xenograft Services for Drug Development Studies of Anticancer Therapeutics

Altogen Labs announced addition of five new in-house validated xenograft models (4T1, BxPC-3, Calu-6, MDA-MB-468, and PANC-1). This will make a total of 89 CDX xenograft models and 29 PDX xenograft models provided by Altogen Labs. Murine models have been used to investigate human cancer, enabling the discovery and development of new anticancer medicines. Xenograft… Continue Reading

Altogen Labs offers xenograft services for drug development of anti-cancer therapeutics

Altogen Labs provides xenograft services for drug development studies of anti-cancer therapeutics by Altogen Labs, Preclinical CRO, 11200 Manchaca Rd, Suite 203 Austin TX 78744 USA (512-433-6177) Contact e-mail: Introduction Xenograft studies fuels the development of new therapeutics efficiently and effectively and remains the gold standard for preclinical oncology research [1]. Xenograft studies, over… Continue Reading

Preclinical Contract Research Studies by Global Health & Pharma

Altogen Labs is a good laboratory practice (GLP) compliant laboratory that provides biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide. Altogen Labs services include safety in vivo toxicology studies (for IND applications), efficacy studies (for regulatory submissions), drug discovery (patent applications), drug development and other types of R&D studies – pharm/tox, bio distribution and imaging studies. Altogen Labs was established in 2009 in Austin,… Continue Reading

Biology CRO Contract Research Services to Accelerate Preclinical and Oncology Research Studies

Altogen Labs, a CRO laboratory located in Austin, Texas (USA), provides preclinical pharmacology and oncology contract research services for pharmaceutical, biotechnology, and academic research institutions worldwide. Company scientists bring years of experience and expertise in life science and drug discovery research services. Altogen Labs offers GLP-compliant research and development services that include preclinical trials to… Continue Reading

Altogen Labs Offers Pre-Clinical CRO Services to Accelerate Pre-Clinical Research Needs

Altogen Labs, a biotechnology company focused on providing biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide, announced pre-clinical contract research services enabling companies to accelerate pre-clinical research needs. Pre-clinical trials assess the toxicity and pharmacological activity of investigative new drugs (INDs) to assess a compound’s therapeutic potential and safety for human use. A… Continue Reading